Geneva (Switzerland), May 7, 2024 – Atopia Therapeutics, a leader in the development of breakthrough asthma and allergy therapies, today announced the appointment of Dr. Grégoire Chevalier as Chief Executive Officer (CEO). Formerly known as HpVac, the Company has repositioned itself under the new name Atopia Therapeutics to better reflect its commitment to addressing the growing global burden of atopic diseases.
Grégoire Chevalier brings over 10 years of research and drug development experience to Atopia Therapeutics. He joins the Company from Enterome, a leading French biotechnology company focused on innovative immunotherapy for cancer, where he spent the last 5 years directing several R&D programs. Throughout his career, he has demonstrated a strong ability to drive strategic initiatives and foster a culture of innovation and excellence. Grégoire will now lead Atopia’s strategy and development and strengthen the overall organization.
Under Grégoire Chevalier’s leadership, Atopia Therapeutics will continue the development of novel treatments that address the underlying mechanisms of atopic diseases. Its lead compound ATP-R13 (formerly: HpVac-R13) is designed as a first-line preventive and therapeutic treatment for a number of type-2 atopic diseases, including asthma, allergic rhinitis, food allergies and atopic dermatitis. The compound has already generated promising data in preclinical studies, including beneficial effects on airway hyperresponsiveness, airway remodeling, and inflammation in mouse models of allergic asthma.
“As we embark on our next phase of growth and expansion, we are thrilled to welcome Grégoire Chevalier as the new CEO of Atopia Therapeutics,” said Board Member Jacques Billy, CFO of Atopia Therapeutics. “Grégoire’s deep industry expertise, coupled with his passion for scientific innovation and patient-centric approach, make him the ideal leader to steer our company towards continued success.”
“I am delighted and grateful to have the opportunity to lead Atopia Therapeutics during this exciting period of growth and transformation,” said Grégoire Chevalier, CEO of Atopia Therapeutics. “I am inspired by the Company’s commitment to advancing cutting-edge therapies for allergic diseases, and I look forward to working with the talented team to deliver impactful solutions for patients in need.”
As part of the rebranding initiative, Atopia Therapeutics has unveiled a refreshed corporate identity, including a new logo and website (www.atopiatx.com), designed to reflect the Company’s innovative spirit and forward-thinking approach.